Eluciderm, Inc., a clinical-stage pharmaceutical company developing small molecule therapeutics to promote healing and regenerative repair of injured tissue, announced today that it received the Wound ...
America’s largest wholesale mortgage lender reported a notable insider sale amid a year of declining share prices.
Southern California has had a flurry of activity—from investments by major companies to acquisitions and an IPO—over the past ...
Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented in a podium session at ...
PRESS RELEASENew Preclinical Data on STX-1, a First-in-Class Senolytic ADC, To Be Presented at AACR 2026Presentations highlight therapy-induced ...
From the classroom to the C-suite, from the court to the community, the 2026 Hall of Fame class reflects the far-reaching ...
First Olmsted syndrome patient dosed in global Phase 1b studyCompany now operating under its new name, Orvida PharmaNESS ZIONA, Israel, April ...
Orvida Pharma (formerly Kamari Pharma), a privately held clinical-stage biotechnology company developing first and ...
Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases - ...
Research and innovation in Texas A&M University's biomedical engineering department often centers around clinical impact on ...
Tissue Cryopreservation Preserves More Future Options The way a patient's tumor tissue is preserved after surgery is ...
ProQR Therapeutics is a high-potential, early-stage RNA editing platform company, but remains pre-proof-of-mechanism in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results